This article looks at the 14 Best Booming Stocks to Buy Right Now.
The S&P 500 registered gains of 16% in 2025, marking the third successive year of double-digit returns after the broad market index rallied 24% in 2023 and then 23% in 2024.
Total gains over the past three years have amounted to approximately 80%, the strongest run over a three-year win streak since the index surged 90% between 2019 and 2021.
A Financial Times survey of major investment banks in December forecast a 10% gain in the S&P 500 in 2026. All banks surveyed anticipate the broad market index to cross the 7,500 mark.
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026. The investment bank forecasts earnings growth will drive returns, supported by a strong economy and ongoing Federal Reserve rate cuts.
Ben Snider, chief US equity strategist at Goldman Sachs, wrote in the report that double-digit profit growth and improved productivity from the use of AI set the market well for a continued bull run.
While Snider acknowledged that high stock valuations and multiples could pose a risk if earnings fall below expectations, he believes valuations this year will largely remain unchanged if interest rates remain steady and earnings remain strong.
The only threat to the stock market, according to the Goldman strategist, is if the economy slows or the Federal Reserve tightens monetary policy, but he does not foresee either in the near term.
With that said, let’s now see the best booming stocks to buy right now.
Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels
Our Methodology
We used screeners to identify U.S.-based stocks with market capitalizations of at least $2 billion that had surged at least 20% over the past three months. To validate the bullish trend, we narrowed our list to companies with a 50-DMA above a 200-DMA. From there, we selected the 14 stocks with the highest average upside in share price and ranked them in ascending order. All data is as of the close of business on January 12, 2026. Additionally, we also included data on hedge fund holdings in these companies as of Q3 2025 to provide further insight into investor interest.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
14 Best Booming Stocks to Buy Right Now
14. Alphatec Holdings, Inc. (NASDAQ:ATEC)
Upside Potential: 39.57%
3M Returns: 34.25%
Number of Hedge Fund Holders: 40
Alphatec Holdings, Inc. (NASDAQ:ATEC) is among the 14 best booming stocks to buy right now. On January 12, the company announced preliminary 2025 financial results and provided its 2026 outlook.
Preliminary total revenue increased 25% for the full year and is expected to be between $763.4 million and $764.4 million, driven primarily by a 26% surge in surgical revenue. The company also reaffirmed its full-year guidance for adjusted EBITDA of $91 million. It ended the year with a cash balance of $161 million.
For fiscal 2026, Alphatec Holdings, Inc. (NASDAQ:ATEC) has projected a revenue of $890 million, of which 90% is expected to be surgical-related. Adjusted EBITDA is anticipated to be around $130 million, while free cash flow for the year is forecast at approximately $20 million.
On the same day, the company announced a strategic agreement with Theradaptive, Inc., under which it would acquire exclusive distribution rights in the United States for Theradaptive’s rhBMP-2 solution, OsteoAdapt. The move is set to further strengthen Alphatec Holdings, Inc. (NASDAQ:ATEC) position in the procedural ecosystem.
Following these developments, Needham and HC Wainwright & Co. reiterated their Buy ratings for the stocks, with price targets of $22 and $24, respectively.
Wall Street has a bullish outlook on the company with a consensus Strong Buy rating. The stock has a one-year average share price target of $24.55, representing an upside of nearly 40%, as of the close on January 12.
Alphatec Holdings, Inc. (NASDAQ:ATEC) is a medical device company focused on the development of technologies for improved surgical treatment of spinal disorders.
13. Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Upside Potential: 42.31%
3M Returns: 318.65%
Number of Hedge Fund Holders: 29
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is among the 14 best booming stocks to buy right now. On January 8, Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on the stock with a share price target of $56.
This update is a reaffirmation of the firm’s revision on the stock on December 9, when it lifted the price target to $56 from $35 after the company shared encouraging data from the Phase 1 study of TERN-701, its lead program to treat chronic myeloid leukemia (CML).
According to TipRanks, Truist told investors that given the efficacy and safety profile demonstrated in the study, the firm sees immense potential in the drug’s ‘frontline’ use. The results showed a 64% major molecular response rate by 24 weeks.
On the same day, Mizuho Securities also reiterated its Outperform rating on the stock, with a price target of $54. The firm believes TERN-701 is a ‘clear potential best-in-disease treatment’ for CML.
During an interview with CNBC last month, CEO Amy Burroughs said the company aimed to have pivotal trials for the drug by the end of 2026.
Overall, Wall Street has a bullish outlook on the stock with a consensus Strong Buy rating. Terns Pharmaceuticals, Inc. (NASDAQ:TERN)’s shares have surged by over 300% in the past three months, and analysts project a further 42.31% upside, as of the close of January 12, based on the stock’s one-year average share price target of $53.75.
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a biopharmaceutical company focused on the development of treatments for serious diseases such as cancer and obesity.
12. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Upside Potential: 45.88%
3M Returns: 173.32%
Number of Hedge Fund Holders: 22
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is among the 14 best booming stocks to buy right now. On January 7, UBS initiated coverage of the stock with a Buy rating and set a $45 price target.
The update comes as part of the firm’s assumption of coverage on 22 biotech firms that have a market capitalization between $300 million and $10 billion. According to UBS, fundamentals for companies in the sector were beginning to shift after a challenging period. The analyst believes this will revive investor confidence, positioning these companies for a strong performance in 2026.
On the same day, Piper Sandler also began coverage of the stock with an Overweight rating and announced a share price target of $40. The research firm noted the potential for the company’s Palazestrant drug to become a significant endocrine treatment in the breast cancer market, which could help drive a major upside for the company.
In October last year, Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) reported encouraging clinical data for the oral medication when combined with Ribociclib, with the results demonstrating promising progression-free survival and tolerability profile.
Analysts have a consensus Strong Buy rating on the stock and anticipate the share price to appreciate about 46% over the next 12 months as of January 12, reflecting Wall Street’s bullish sentiment toward the biopharmaceutical company.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is focused on the development of treatments for patients with breast cancer and other serious diseases. The stock has had impressive returns over the past three months, gaining 173% over the period.
11. Structure Therapeutics Inc. (NASDAQ:GPCR)
Upside Potential: 49.94%
3M Returns: 131.66%
Number of Hedge Fund Holders: 42
Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have gained over 130% in the past three months, with a major surge since early December after reporting positive data related to its oral obesity pill.
A study testing aleniglipron on obese or overweight patients, with one or more co-morbidities tied to weight, demonstrated a weight loss of 11.3% after being treated for 36 weeks at a dosage of 120 mg. This was a significant development, given that most of the market is concentrated in injectables.
Structure Therapeutics Inc. (NASDAQ:GPCR) also shared that there is another clinical research ongoing, testing participants with a 240 mg dose, which produced even better results, with a weight loss of 15.3% at 36 weeks.
In other news, on December 17, the company announced that it was beginning the first human-based trial of ACCG-2671, an oral small-molecule amylin receptor to treat obesity.
Wall Street analysts have a bullish outlook for the stock, with a consensus Strong Buy rating and a one-year average share price target of $104, representing an upside of 49.94%, as of the close on January 12.
Recent analyst updates include one from LifeSci Capital on January 6, where it reiterated a Buy rating on the stock with a price target of $107. This followed BMO Capital maintaining its Outperform rating on January 2, with a price target of $130.
Structure Therapeutics Inc. (NASDAQ:GPCR) is a biotechnology company focused on the development of treatments for chronic metabolic conditions.
10. Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Upside Potential: 58.06%
3M Returns: 57.35%
Number of Hedge Fund Holders: 31
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the 14 best booming stocks to buy right now. The stock is surging and has gained over 57% in the last three months, as of the close on January 12.
Shares closed 3% higher on Tuesday, January 13, after the company provided a corporate update and outlined its priorities for 2026.
Major milestones for the current year include the expectation of top-line findings for Sevasemten by the fourth quarter, which would be the first approved therapy for patients with Becker disease.
On the other hand, Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is also anticipating Phase 2 results for its selective cardiac sarcomere modulator, EDG-7500, during the first half of the year, to treat hypertrophic cardiomyopathy (HCM).
The stock has a one-year average share price target of $38.14, representing an upside potential of 58.06%, as of January 12. Wall Street analysts remain bullish on Edgewise with a consensus Strong Buy rating.
Recently, it has been on the radar of several research firms. On December 24, Stifel Nicolaus maintained a Hold rating on the stock with a $16 price target. On the same day, JPMorgan analyst Tessa Romero also reiterated the firm’s Overweight rating on the stock.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a biopharmaceutical company developing therapeutics for muscular dystrophies and cardiac diseases.
9. Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Upside Potential: 59.12%
3M Returns: 28.18%
Number of Hedge Fund Holders: 35
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is among the 14 best booming stocks to buy right now. Its shares have gained over 28% in the last three months, with Wall Street anticipating a further uptick of nearly 60%, as of the close of business on January 12.
However, on January 6, Wolfe Research downgraded the stock to Peer Perform from Outperform, and according to a report on TipRanks, the firm also removed its $92 price target for the company’s shares.
In a research note to investors, Wolfe Research described the stock as ‘a poor investment in 2026’, citing a lack of catalysts that could drive an upside and valuation concerns about the stock among investors. However, the firm’s analyst still considers Kymera Therapeutics, Inc. (NASDAQ:KYMR) a good investment over the long term.
On the same day, BTIG reiterated its Buy rating on the stock with a share price target of $138. Earlier on January 5, Citigroup also kept its Buy rating and maintained an earlier price target of $110 on its shares.
In December, the company announced that it had received Fast Track designation from the FDA for its KT-621 oral STAT6 degrader to treat atopic dermatitis. This followed promising results from the BroADen Phase 1b clinical trial that demonstrated the potential of treating various Type 2 inflammatory diseases across metrics through a once-daily intake.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a biopharmaceutical company developing protein degradation therapies to address critical medical problems.
8. Vera Therapeutics, Inc. (NASDAQ:VERA)
Upside Potential: 59.45%
3M Returns: 52.89%
Number of Hedge Fund Holders: 36
Vera Therapeutics, Inc. (NASDAQ:VERA) is among the 14 best booming stocks to buy right now. On January 7, the company announced that the U.S. Food and Drug Administration (FDA) had accepted Atacicept’s Biologics License Application (BLA) for priority review to treat adult patients of immunoglobulin A nephropathy (IgAN).
The application was submitted under the Accelerated Approval Program and has been granted a target action date of July 7, 2026. The drug’s approval by the FDA would let patients administer their treatments at home through an injection to be used once a week.
Vera Therapeutics, Inc. (NASDAQ:VERA)’s founder and CEO, Marshall Fordyce, M.D., believes the approval would help in enhancing the care of IgAN, as Atacicept would become the first B-cell modulator that simultaneously targets both APRIL and BAFF.
Recent findings from the ORIGIN 3 trial demonstrated the efficacy of Atacicept, with participants treated with the drug experiencing a 46% decline in proteinuria from baseline and a 42% reduction in urine protein-to-creatinine ratio compared with placebo at week 36.
Vera Therapeutics, Inc. (NASDAQ:VERA)’s shares have returned nearly 53% over the past three months, and Wall Street’s average one-year share price target of $74.08 projects a further upside of 59.45% ahead, as of January 12.
Recent analyst updates include Guggenheim and LifeSci Capital reiterating their Buy ratings on the stock on January 7, with price targets of $56 and $70, respectively.
Vera Therapeutics, Inc. (NASDAQ:VERA) is a clinical-stage biotech company that develops treatments for complex immunological diseases.
7. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Upside Potential: 60.14%
3M Returns: 23.73%
Number of Hedge Fund Holders: 31
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is among the 14 best booming stocks to buy right now. On January 12, Goldman Sachs analyst Richard Law upgraded the stock’s rating to Buy from Neutral, with a share price target of $67.
The adjustment followed promising results from a trial investigating the impact of atumelnant on congenital adrenal hyperplasia (CAH). The findings revealed a 67% reduction in A4 in Cohort 4, replicating the results in the first three cohorts. Moreover, about 7 in 8 participants maintained a reduction in androgen, despite cutting the glucocorticoid dosage to protocol levels.
In other news, Citizens analyst Jonathan Wolleben on January 8 slightly cut the firm’s price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $105 from $108, while maintaining an earlier Outperform rating on the shares.
The analyst cited a survey by American endocrinologists that revealed ‘positive early experience’ with the company’s recently launched drug, Palsonify, to treat acromegaly. In a research note to investors, Law said that the survey supported the Q4 preliminary net product revenue of over $5 million that the company announced earlier in the week.
According to a report on TipRanks, Citizens expects Palsonify to continue exceeding expectations in 2026.
Overall, Wall Street analysts have a bullish outlook on the stock with a consensus Strong Buy rating with a one-year average share price target of $88.64, representing an upside potential of 60.14% as of the close on January 12.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a biopharmaceutical company that develops treatments for rare endocrine diseases and endocrine-related tumors.
6. Immunome, Inc. (NASDAQ:IMNM)
Upside Potential: 61.40%
3M Returns: 47.92%
Number of Hedge Fund Holders: 22
Immunome, Inc. (NASDAQ:IMNM) is among the 14 best booming stocks to buy right now. The company’s shares are surging and have gained 48% in the last three months.
The returns have been driven primarily by bullish outlooks on the stock’s potential to treat desmoid tumors.
On December 15, Immunome, Inc. (NASDAQ:IMNM) shared positive topline results from the Phase 3 RINGSIDE trial, demonstrating an improved survival rate without progression, when compared with a placebo. The results showed the drug decreased the likelihood of death or disease progression by 84%.
According to the company’s press release, 156 patients were part of the trial, of which about 56% of them had their tumors disappear or shrink in size, in contrast with 9% on placebo. Based on the results, Immunome, Inc. (NASDAQ:IMNM) said it plans on seeking approval from the FDA for Varegacestat in the second quarter of 2026.
Following the results, Guggenheim, on December 22, revised its price target on the stock to $35 from $25, while keeping a Buy rating on the shares. The research firm expects approval for Varegacestat from the FDA and says the drug could grab a major chunk of the share in America’s desmoid tumors market.
Evercore ISI Group and Lake Street also lifted their price targets on Immunome, Inc. (NASDAQ:IMNM) to $40 from $18, and $32 from $22, while reiterating their Outperform and Buy ratings, respectively.
Wall Street analysts have a consensus Strong Buy rating on the stock, with a one-year average share price target of $33.20, representing an upside potential of 61.40%, as of January 12.
Immunome, Inc. (NASDAQ:IMNM) is an oncology company that develops treatments and therapies for cancer patients.
5. Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
Upside Potential: 65.63%
3M Returns: 421.31%
Number of Hedge Fund Holders: 33
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is among the 14 best booming stocks to buy right now, with staggering three-month returns of over 420%.
On January 12, Wedbush analyst Laura Chico lifted the price target on the stock to $95 from $83, citing the company’s recent public offering as the basis for the adjustment. According to a press release later during the day, the offering generated around $621 million in net proceeds.
Despite the revision, the new price target represents a downside of 66% from Tuesday’s close of $280.86. Wedbush maintained an Underperform rating for the shares.
While the firm has a bearish outlook for Praxis Precision Medicines, Inc. (NASDAQ:PRAX), Wall Street on a whole remains bullish with a consensus Strong Buy rating and a one-year average share price target of $$456.71, representing an upside of 65.63% as of January 12.
In other news, the biopharmaceutical company on Monday also shared its corporate outlook for 2026 and mentioned that multiple readouts were scheduled over the next 12-24 months. It is also planning two New Drug Applications (NDA) submissions in February this year to the FDA for Ulixacaltamide in essential tumor and Relutrigine for SCN2A- and SCN8A-DEE.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a biopharmaceutical company that uses genetics insights to develop therapies for central nervous system disorders.
4. Spyre Therapeutics, Inc. (NASDAQ:SYRE)
Upside Potential: 72.77%
3M Returns: 69.15%
Number of Hedge Fund Holders: 21
Spyre Therapeutics, Inc. (NASDAQ:SYRE) is among the 14 best booming stocks to buy right now. On January 5, Wells Fargo reiterated a Buy rating on the stock, with a price target of $40.
The update follows Mizuho’s initiation of coverage on the stock on December 18 with an Outperform rating and a share price target of $53, where it cited potential in the company’s pipeline of anti-monoclonal antibodies to treat inflammatory bowel disease (IBD).
In November, the biotech company shared positive findings from its Phase 1 human trial of SPY003, an extended half-life antibody to cure IBD. The tests performed on 59 participants with varying doses showed that the drug was well received at all levels, with a half-life of nearly 85 days, strengthening the case for quarterly or two annual maintenance doses.
According to TipRanks, in a research note to investors, Mizuho praised the company’s expertise in testing new combinations for treatments, which could help drive growth in the future. The firm projects Spyre Therapeutics, Inc. (NASDAQ:SYRE)’s global sales to reach $1.7 billion by 2035.
Wall Street analysts have a bullish outlook on the stock with a consensus Strong Buy rating and a one-year average share price target of $56.67, representing an upside of 72.77% as of January 12.
The company’s shares have surged by over 69% in the past three months, driven by growing investors’ optimism from trial results for SPY003, promising recent analyst updates, and third-quarter results in November, which showed a sharp decline in net loss from $69 million in the prior year’s period to $11.2 million.
Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a biotechnology company focused on developing treatments for inflammatory bowel and rheumatic diseases.
3. Nuvation Bio Inc. (NYSE:NUVB)
Upside Potential: 76.16%
3M Returns: 75.40%
Number of Hedge Fund Holders: 39
Nuvation Bio Inc. (NYSE:NUVB) is among the 14 best booming stocks to buy right now. On January 12, the oncology company announced that it had entered into an exclusive licensing and collaboration agreement with Eisai Co. Ltd. to expand the global reach of its lung cancer pill.
Taletrectinib is currently approved for use by patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in the United States, China, and Japan. However, the agreement has now granted Eisai the rights to develop and commercialize the drug for the treatment of the disease in Europe, the Middle East, North Africa, India, and beyond in several other countries.
Nuvation Bio Inc. (NYSE:NUVB), in a press release, said it would retain full commercialization rights in the United States to maintain its focus on activities in the country. It will also lead global development and continue to focus on ongoing research studies.
In other news, on the same day, the company shared preliminary results for the fourth quarter and full year 2025, with IBTROZI’s (taletrectinib) net product revenue at $15.7 million for the fourth quarter, bringing the total to $24.7 million since its launch in June last year.
Following the results, H.C. Wainwright lowered its price target on the stock to $17 from $18, while maintaining a Buy rating. The firm noted that IBTROZI’s quarterly revenue largely came in line with expectations.
Wall Street analysts have a consensus Strong Buy rating on the stock, with an average share price target of $11.38, representing an upside of 76.16% as of the close on January 12.
Nuvation Bio Inc. (NYSE:NUVB) is a biopharmaceutical company focused on the development of novel oncology therapies.
2. Alumis Inc. (NASDAQ:ALMS)
Upside Potential: 78.62%
3M Returns: 372.75%
Number of Hedge Fund Holders: 26
Alumis Inc. (NASDAQ:ALMS) is among the 14 best booming stocks to buy right now. On January 9, HC Wainwright & Co. lifted its price target on the stock to $40 from $20, while maintaining a Buy rating on the shares.
The adjustment came after the company shared promising results earlier in the week from the Phase 3 ONWARD1 and ONWARD2 trials evaluating the efficacy of envudeucitinib in patients with moderate to severe plaque psoriasis.
Both trials achieved their primary and secondary endpoints. Moreover, the results demonstrated safe usage and tolerability among patients, who also reported a significant improvement in their quality of life through eased itching. Alumis Inc. is planning to file for the drug’s approval with the FDA during the latter half of 2026.
HC Wainwright & Co. believes the results have ‘reset expectations’ in the area of oral tyrosine kinase 2 (TYK2). The firm sees a strong chance of the FDA approving envudeucitinib, which could lead to a major revenue surge for the company.
Several other research firms, including Wells Fargo and Morgan Stanley, also revised their positions on the stock following the announcement of trial results by increasing their price targets on Alumis Inc. (NASDAQ:ALMS).
As of the close of business on January 12, Wall Street analysts have a consensus Strong Buy rating on the stock with a one-year average share price target of $37.67, representing an upside of 78.62%.
Alumis Inc. (NASDAQ:ALMS) is a biopharmaceutical company with expertise in developing targeted therapies to treat immune-mediated diseases.
1. Dyne Therapeutics, Inc. (NASDAQ:DYN)
Upside Potential: 119.93%
3M Returns: 23.49%
Number of Hedge Fund Holders: 45
Dyne Therapeutics, Inc. (NASDAQ:DYN) is among the 14 best booming stocks to buy right now, with returns of over 23% in the last three months. Wall Street analysts have a consensus Strong Buy rating on the stock and project a further 120% upside as of the close on January 12.
Recent analyst updates include Evercore ISI’s Gavin Clark-Gartner on December 17, trimming the firm’s price target on the stock to $36 from $38, while maintaining an earlier Outperform rating.
According to TipRanks, the firm praised the company for its functionality and meeting expectations on metrics such as safety and efficacy. Despite the cut, the revised price target represents an upside potential of over 100% from Monday’s close.
Earlier on December 10, Oppenheimer upgraded the stock’s rating to Outperform and lifted its price target to $40 from $11 on December 10, citing the anticipated Phase 3 trial readout for competitor Avidity’s RNA therapy, del-desiran in myotonic dystrophy type 1, in the second half of 2026.
According to Oppenheimer, another significant upside catalyst for Dyne Therapeutics, Inc. (NASDAQ:DYN) this year could be the success of its zeleciment basivarsen therapeutic to treat patients living with myotonic dystrophy type 1 (DM1). Moreover, the likelihood of the FDA reviewing the company’s candidate for Duchenne muscular dystrophy (DMD) could also help the stock rally.
Dyne Therapeutics, Inc. (NASDAQ:DYN) is a healthcare company focused on developing treatments for patients of genetically driven neuromuscular diseases.
While we acknowledge the potential of DYN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DYN and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
